Cue Biopharma, Inc. Retained Earnings
Cue Biopharma, Inc. (CUE) had Retained Earnings of -$526.71 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$526.71M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$373.64M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$368.47M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$370.05M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$526.71M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$373.64M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$368.47M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | -$370.05M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$362.60M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$354.12M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$341.86M 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$332.37M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$323.71M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$313.54M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$301.19M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$287.75M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | -$276.75M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$263.56M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -$250.46M 10-K · filed 2024-03-28 | -$250.46M 10-K · filed 2023-03-21 |
| 2022-09-30 | -$235.86M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$224.91M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$211.70M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | -$197.45M 10-K · filed 2023-03-21 | |
| 2021-09-30 | -$189.06M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$176.07M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | -$165.79M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | -$153.29M 10-K · filed 2022-03-16 | |
| 2020-09-30 | -$142.18M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | -$132.15M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | -$121.32M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$108.50M 10-K · filed 2021-03-09 | |
| 2019-09-30 | -$99.58M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | -$92.59M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$83.07M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | -$71.80M 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$60.18M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | -$47.63M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | -$40.34M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | -$32.82M 10-K · filed 2019-03-14 | -$32.82M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |